Matias Clinical Laboratory INC

Matias Clinical Laboratory INC was paid $4.00M by Medicaid between Jan 2018 and Apr 2022, across 138 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 20% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#117 of 561

Median peer was paid$222K

This provider vs. median18×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	59,308	$497K
2019	67,522	$404K
2020	97,446	$649K
2021	116,062	$2.26M
2022	10,081	$190K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	20%	19,183	6,160	$783K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	16%	22,024	10,083	$646K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	8.7%	16,096	6,186	$347K
87631		7.0%	14,386	5,244	$279K
87634		6.4%	15,868	6,146	$256K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	5.0%	2,035	1,651	$200K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.8%	16,463	5,285	$192K
87486		3.9%	15,975	6,383	$155K
87581		3.4%	16,619	6,454	$135K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	1.8%	3,785	3,595	$72K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.5%	1,535	1,292	$61K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.3%	4,058	1,336	$53K

126 more codes

86235		1.2%	2,291	$50K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.2%	3,028	$48K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.2%	2,908	$48K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.1%	4,040	$43K
87186		<1%	2,804	$38K
87481		<1%	3,787	$36K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	1,895	$34K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	2,992	$28K
86780		<1%	3,854	$24K
86147		<1%	2,072	$21K
87640		<1%	3,999	$19K
87500		<1%	3,865	$19K
87653		<1%	3,787	$19K
87496		<1%	3,787	$19K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	3,634	$19K
87529		<1%	3,791	$18K
80050	General health panel	<1%	811	$14K
82172		<1%	2,432	$13K
83880		<1%	1,994	$12K
83516		<1%	2,290	$11K
80061	Lipid panel	<1%	4,767	$10K
84403		<1%	1,866	$9K
82607		<1%	3,302	$9K
84270		<1%	2,287	$8K
82627		<1%	2,314	$8K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	553	$8K
84681		<1%	2,218	$8K
83970		<1%	1,363	$8K
84144		<1%	2,063	$7K
83036	Hemoglobin; glycosylated (A1C)	<1%	4,738	$7K
86696		<1%	2,272	$7K
82670		<1%	1,535	$7K
83090		<1%	2,496	$7K
82746		<1%	2,712	$6K
86769		<1%	814	$6K
82533		<1%	2,252	$6K
84480		<1%	2,761	$6K
83003		<1%	2,063	$6K
86803		<1%	2,643	$6K
82495		<1%	1,739	$6K
82728		<1%	2,770	$6K
87632		<1%	67	$5K
86141		<1%	2,482	$5K
84146		<1%	1,684	$5K
86225		<1%	2,291	$5K
83695		<1%	2,403	$5K
83001		<1%	1,665	$5K
86704		<1%	2,472	$5K
86695		<1%	2,253	$5K
83002		<1%	1,525	$5K
86665		<1%	1,470	$5K
84439		<1%	3,012	$4K
86706		<1%	2,519	$4K
87340		<1%	2,688	$4K
86709		<1%	2,218	$4K
86644		<1%	1,549	$4K
86664		<1%	1,437	$4K
86038		<1%	1,792	$4K
84153		<1%	1,259	$3K
83735		<1%	2,748	$3K
83550		<1%	2,690	$3K
82150		<1%	2,523	$3K
83690		<1%	2,402	$3K
83520		<1%	332	$3K
83540		<1%	2,735	$3K
82550		<1%	2,343	$2K
80053	Comprehensive metabolic panel	<1%	5,399	$2K
86304		<1%	743	$2K
82378		<1%	792	$2K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	437	$2K
84550		<1%	3,295	$2K
86146		<1%	614	$2K
84402		<1%	523	$2K
86376		<1%	997	$2K
86800		<1%	889	$2K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	179	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	5,287	$2K
85651		<1%	2,948	$2K
87652		<1%	209	$2K
84443	Thyroid stimulating hormone (TSH)	<1%	4,597	$2K
81001		<1%	2,475	$1K
85730		<1%	297	$1K
82232		<1%	373	$849.77
87150		<1%	386	$837.90
81000		<1%	1,451	$569.28
86300		<1%	278	$468.60
85610		<1%	310	$406.51
84436		<1%	2,523	$359.99
84479		<1%	2,503	$294.18
81225		<1%	100	$233.09
84466		<1%	247	$226.46
84481		<1%	114	$219.64
84207		<1%	25	$210.87
86200		<1%	176	$185.43
86256		<1%	45	$172.62
82248		<1%	162	$171.09
87086	Culture, bacterial; quantitative colony count, urine	<1%	120	$170.83
84425		<1%	26	$159.28
82107		<1%	21	$152.10
81227		<1%	90	$139.85
86705		<1%	121	$128.64
87541		<1%	386	$119.70
82553		<1%	190	$106.38
80048	Basic metabolic panel (calcium, ionized)	<1%	86	$75.01
81355		<1%	69	$70.56
86430		<1%	40	$65.79
84075		<1%	78	$56.48
86340		<1%	57	$51.40
83615		<1%	202	$47.38
84460		<1%	64	$46.93
84450		<1%	64	$45.89
82247		<1%	62	$44.46
84154		<1%	14	$37.65
82977		<1%	20	$34.37
82043		<1%	14	$23.70
82040		<1%	53	$23.66
81015		<1%	1,278	$21.52
82947		<1%	73	$16.08
84100		<1%	13	$12.92
83718		<1%	12	$11.18
81003		<1%	295	$1.78
84155		0%	25	$0.00
86481		0%	63	$0.00
81226		0%	101	$0.00
87505		0%	209	$0.00
86301		0%	24	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialVILLARBA, EMILIO (PRESIDENT)